Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Akeso
- Target Recruit Count
- 30
- Registration Number
- NCT05247684
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 130
- Registration Number
- NCT05235542
- Locations
- 🇨🇳
Shanghai Renji Hospital, Shanghai, China
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Akeso
- Target Recruit Count
- 636
- Registration Number
- NCT05235516
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Guizhou Cancer Hospital, Guiyang, Guizhou, China
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 114
- Registration Number
- NCT05229497
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 700
- Registration Number
- NCT05226598
- Locations
- 🇪🇸
Hospital Clinico San Carlos-Oncology Department ( Site 1107), Madrid, Spain
🇨🇳Jilin Cancer Hospital-oncology department ( Site 2603), Changchun, Jilin, China
🇨🇳Zhejiang Cancer Hospital-Oncology ( Site 2612), Hangzhou, Zhejiang, China
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)
- Conditions
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 460
- Registration Number
- NCT05224141
- Locations
- 🇯🇵
National Cancer Center Hospital East ( Site 3002), Kashiwa, Chiba, Japan
🇨🇦Lakeridge Health ( Site 0102), Oshawa, Ontario, Canada
🇩🇪LungenClinic Grosshansdorf-Onkologie ( Site 0903), Grosshansdorf, Schleswig-Holstein, Germany
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05213312
- Locations
- 🇨🇳
180 Fenglin Road, Shanghai, China
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT05211323
- Locations
- 🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-10-04
- Target Recruit Count
- 32
- Registration Number
- NCT05203913
- Locations
- 🇮🇹
Roberto iacovelli, Roma, Italy
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT05198830
- Locations
- 🇺🇸
Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States
🇺🇸Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.